KRAS and neoplasm: In the KPC cell–derived orthotopic mouse PDAC model, MRTX1133 treatment significantly decreased glucose utilization of the tumors shown by 18F-FDG PET/CT (Figure 2H) and also inhibited tumor growth, but interestingly, the inhibition of KRAS dramatically sensitized the KPC tumors to anti–PD-1-based ICB (Figure 2I).